Jazz Pharmaceuticals PLC Form 4 insider transactions

Mary Elizabeth Henderson, SVP of Technical Operations at Jazz Pharmaceuticals, reports the acquisition of ordinary shares through restricted stock units.

Samantha Pearce, EVP and Chief Commercial Officer of Jazz Pharmaceuticals, reports the acquisition of restricted stock units.

Renee D. Gala, President & COO of Jazz Pharmaceuticals, reports the acquisition of restricted stock units under the company's 2011 Equity Incentive Plan.

Philip L. Johnson, EVP & Chief Financial Officer of Jazz Pharmaceuticals, reports the acquisition of ordinary shares and restricted stock units.

Patricia Carr, SVP, Chief Accounting Officer of Jazz Pharmaceuticals, reports the acquisition and disposal of ordinary shares and derivative securities.

Neena Patil, EVP & Chief Legal Officer of Jazz Pharmaceuticals, reports the sale and acquisition of ordinary shares and restricted stock units.

Bruce Cozadd, Chairman and CEO of Jazz Pharmaceuticals, reports acquisition of restricted stock units and sale of ordinary shares.

Jazz Pharmaceuticals CEO Bruce Cozadd sold 1,500 ordinary shares at $122.31 per share on February 3, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Robert Iannone, EVP, G R&D and CMO of Jazz Pharmaceuticals, reports the acquisition of 7,506 ordinary shares and the disposal of 2,181 shares to cover tax obligations following the vesting of performance share awards.

Jazz Pharmaceuticals CEO Bruce Cozadd acquired 29,559 ordinary shares through the vesting of a performance share award, while 13,840 shares were withheld for tax obligations.

Jazz Pharmaceuticals' President & COO, Renee D Gala, acquired shares through performance award vesting and sold some to cover tax obligations.

Patricia Carr, SVP and Chief Accounting Officer at Jazz Pharmaceuticals, acquired 1,641 ordinary shares following the vesting of performance-based awards.

Jazz Pharmaceuticals' EVP & Chief Legal Officer, Neena Patil, acquired shares following the vesting of performance awards and sold shares to cover tax obligations.

Executive Vice President and Chief Commercial Officer of Jazz Pharmaceuticals, Samantha Pearce, reports acquisition of shares through performance award vesting and a stock purchase plan, along with a disposition of shares to cover tax obligations.

Bruce C Cozadd, Chairman and CEO of Jazz Pharmaceuticals plc, sold 1,500 ordinary shares on January 2, 2025, at a price of $123.43 per share.

Renee D Gala, President & COO of Jazz Pharmaceuticals, sold 80 ordinary shares to cover tax obligations and acquired 215 shares through an employee stock purchase plan.

Jazz Pharmaceuticals CEO Bruce C. Cozadd sold 2,000 ordinary shares on December 2, 2024, under a pre-arranged 10b5-1 trading plan.

Patricia Carr, SVP and Chief Accounting Officer at Jazz Pharmaceuticals, sold 53 ordinary shares on December 2, 2024.

Neena M Patil, EVP & Chief Legal Officer of Jazz Pharmaceuticals, sold 3,700 ordinary shares at an average price of $123.41 on November 8, 2024.

Bruce Cozadd, Chairman and CEO of Jazz Pharmaceuticals, sold 1,000 ordinary shares at a price of $110.84 on November 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Mary Elizabeth Henderson, SVP of Technical Operations at Jazz Pharmaceuticals, sold 1,410 ordinary shares to cover tax obligations arising from vested restricted stock units.

Director Patrick Enright reports acquisition and disposal of Jazz Pharmaceuticals ordinary shares and restricted stock units.

Director Rick Winningham reports acquisition and disposal of Jazz Pharmaceuticals ordinary shares, including shares sold to cover tax obligations from vesting restricted stock units.

Director Mark Smith reports acquisition and disposal of Jazz Pharmaceuticals ordinary shares related to restricted stock units.

Director Norbert Riedel reports acquisition and disposal of Jazz Pharmaceuticals plc ordinary shares, including shares sold to cover tax obligations.

Director Anne O'Riordan reports acquisition and disposal of Jazz Pharmaceuticals plc ordinary shares related to restricted stock units.

Director Kenneth O'Keefe reports acquisition and disposal of Jazz Pharmaceuticals shares, including those to cover tax obligations.

Director Heather McSharry reports acquisition and disposal of Jazz Pharmaceuticals ordinary shares, including shares sold to cover tax obligations.

Director Jennifer Cook of Jazz Pharmaceuticals reports acquisition and disposal of ordinary shares, including shares sold to cover tax obligations from vesting restricted stock units.

Samantha Pearce, EVP and Chief Commercial Officer of Jazz Pharmaceuticals, reports acquisition of shares and restricted stock units.